2nd Quarter - Report

COVINGTON & BURLING LLP for ZYMERGEN INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies

Foreign entity interest: Foreign entities identified on form LD-1 have an interest in the lobbying issues.

LobbyistCovered position, as disclosed
GARY HEIMBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies

Foreign entity interest: Foreign entities identified on form LD-1 have an interest in the lobbying issues.

LobbyistCovered position, as disclosed
GARY HEIMBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Science/Technology SCI

Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies

Foreign entity interest: Foreign entities identified on form LD-1 have an interest in the lobbying issues.

LobbyistCovered position, as disclosed
GARY HEIMBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.